CAR-T therapy plays a key role in cancer immunotherapy and belongs to adoptive T cell transfer (ACT). At the beginning of June, the annual meeting of the American Society of Clinical Oncology (ASCO) was held in which CAR T therapy was still a hot topic. And Celgene and Bluebird have released the latest cell therapy data, showing once again the potential of this new cancer immunotherapy.
In 2017, the first two CAR-T cell therapies approved by FDA—Kymriah of Novartis and Yescarta of Kite ... Más informaciones
In 2017, the first two CAR-T cell therapies approved by FDA—Kymriah of Novartis and Yescarta of Kite ... Más informaciones
